A new director for AusBiotech and the appointment of experienced industry executive and PBAC member Michelle Burke as deputy chair.
At its annual general meeting, the association confirmed CSL's senior vice president of organisation transformation and external affairs, Dr Andrea Douglas, would be succeeded on its board by the company's Dr Serge Scrofani.
Dr Douglas served on the board for six years. “Andrea has delivered valuable service to AusBiotech and the sector during her AusBiotech Board tenure. On behalf of the Board, I extend our sincere thanks to Andrea for her dedicated contribution and insights, particularly during AusBiotech’s change in CEO-leadership last year,” said AusBiotech chair, Ms Julie Phillips.
Dr Scrofani is CSL's vice president of strategy and corporate development. He is responsible for evaluating, negotiating and closing on global strategic growth opportunities through mergers and acquisitions.
He has held various roles at CSL both locally and internationally, including global head of business development for its largest subsidiary, CSL Behring. Prior to this, he joined Zenyth (formerly Amrad) in 1998 and held positions in both research and business development before its acquisition by CSL in 2006.
“We are delighted to welcome Dr Serge Scrofani to the AusBiotech Board. His experience in big pharma and in growth markets, including China, will help us identify more international opportunities for AusBiotech members,” said Ms Phillips.
The association also confirmed the election of Michelle Burke to the newly created role of deputy chair. Ms Burke, who is the industry nominated member on the PBAC, has been on the AusBiotech board since 2012.